Last reviewed · How we verify
Biliary tract cancer
Approved treatments
- Tibsovo · Servier
Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML. - Pemazyre · Incyte Corp
Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Biliary tract cancer patent landscape — cliff calendar, originator estates, attackable patents
- Biliary tract cancer treatment landscape brief
- Biliary tract cancer treatment updates RSS
Frequently asked questions about Biliary tract cancer
What drugs treat Biliary tract cancer?
Tracked treatments include Tibsovo, Pemazyre.
What is the treatment for Biliary tract cancer?
Standard treatment for Biliary tract cancer includes Tibsovo, Pemazyre. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Biliary tract cancer patent cliff · Biliary tract cancer CI report
- Treatment: Tibsovo · Servier
- Treatment: Pemazyre · Incyte Corp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing